| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
EDITORIAL |
Treatment of Behçet's syndrome
The Hon. Consulting Rheumatologist, Royal London Hospital, London E1 1BB, UK
Correspondence to: C.G. Barnes, Little Hoopern, Chagford, TQ13, 8B2, UK. E-mail: cgbarnes@btinternet.com
| The first 150 words of the full text of this article appear below. |
Whenever an article on Behçet's syndrome (BS) is published the introduction almost always is repetitive, reminding the reader that this is a multisystem disorder of unknown aetiology the underlying pathology being a vasculitis, which follows a chronic and relapsing course. The paper by Mat et al. [1] in this journal is no exception. The use of the name ‘Behçet's syndrome’, rather than ‘Behçet's disease’, is preferred by many of those interested in the condition since it may present with considerable variation in manifestations and severity between patients, and indeed in the prevalence of individual manifestations in different parts of the world, especially that of gut involvement [2].
As is shown below, the wide variation in the manifestations with which the patient may present may lead to referral to one of a number of different specialities: (alphabetically) dermatology, genitourinary medicine, gynaecology, internal medicine, ophthalmology, oral medicine,